预约演示
更新于：2025-07-19
Dobutamine Hydrochloride
盐酸多巴酚丁胺
更新于：2025-07-19
概要
基本信息
药物类型 小分子化药 |
别名 (±)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol、3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenylethylamine、4-{2-[3-(4-Hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol + [15] |
作用方式 激动剂 |
作用机制 adrenergic receptor激动剂(肾上腺素能受体家族激动剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H24ClNO3 |
InChIKeyBQKADKWNRWCIJL-UHFFFAOYSA-N |
CAS号49745-95-1 |
关联
76
项与 盐酸多巴酚丁胺 相关的临床试验NCT07000994
Dobutamine During Major Abdominal Surgery: A Randomized Pilot Trial (PUSH-1)
CTIS2023-504915-34-00
Dose-finding for dobutamine during transitional circulation in the very preterm infant - NeoCirc-002 TRIAL
NCT06878742
Dose-finding for Dobutamine During Transitional Circulation in the Very Preterm Infant
100 项与 盐酸多巴酚丁胺 相关的临床结果
登录后查看更多信息
100 项与 盐酸多巴酚丁胺 相关的转化医学
登录后查看更多信息
100 项与 盐酸多巴酚丁胺 相关的专利（医药）
登录后查看更多信息
9,747
项与 盐酸多巴酚丁胺 相关的文献（医药）2025-09-01JOURNAL OF PHARMACEUTICAL SCIENCES
Physicochemical compatibility investigation of ciprofol injection with eight cardiovascular drugs during simulated Y-site administration
Article
作者: Chen, Peng ; Liu, Qipeng ; Chen, Fuchao ; Wu, Jing ; Fang, Baoxia ; Deng, Wenya
The intravenous pharmacotherapy in patients with critically ill and perioperative intravenous anesthesia is extremely challenging due to the large number of drugs administered. In-line incompatibility remains a significant safety concern. We therefore evaluated the physico- chemical compatibility of combinations of ciprofol injection with cardiovascular drugs during simulated Y-site administration frequently used in intensive care unit setting or intravenous anesthesia. Ciprofol injection was mixed with clinical concentrations of dopamine, sodium nitroprusside, dobutamine, phentolamine, papaverine, nitroglycerin, metaraminol and methoxamine solution at a 1:1 vol ratio under ambient conditions (25 ± 1 °C). Physicochemical compatibility changes in appearance, pH values, Zeta potential, particle size/polydispersity index (PDI), osmotic pressure, and relative percentage content are observed at predetermined time points (0, 2, 4, 6, and 8 h). During the 8-hour study period, the pH values change of all drug mixture remained within ±0.4. The relative drug concentration was maintained between 95 % and 105 %. The mean particle size was in the range of 200 to 220 nm, with a PDI below 0.2. Osmotic pressure changes were consistently <6 %. Notably, the Zeta potential of the metaraminol-ciprofol mixture exhibited a variation exceeding ±10 mV. Microscopic imaging analysis showed that the droplet sizes of dopamine-ciprofol, metaraminol-ciprofol, and papaverine-ciprofol mixtures, increased significantly. Based on this studies, ciprofol injection demonstrated compatibility and stability when administered via Y-site infusion with sodium nitroprusside, dobutamine, methoxamine, phentolamine, and nitroglycerin for up to 8 h at room temperature. However, the combination of ciprofol with dopamine, metaraminol, or papaverine was incompatibility during infusion. pH is a significant factor that could potentially influence the stability and compatibility of the combinations. Clinical strategies such as the use of inline filters and post-infusion irrigation tubes can prevent these risks.
2025-08-01JHLT Open
Prognostic value of the vasoactive-inotropic score in predicting outcomes following LVAD implantation
Article
作者: Rusia, Akash ; Ogbue, Patrick ; Michael DiMaio, J ; Kabra, Nitin ; Dorton, Cody W ; George, Timothy J ; Rawitscher, David A ; Pickering, Taylor ; Afzal, Aasim ; McCullough, Kyle A ; Milligan, Greg
Background:
Vasoplegia frequently complicates left ventricular assist device (LVAD) implantation, yet its impact on outcomes is not fully understood. The vasoactive-inotropic score (VIS), which quantifies vasoactive support, may predict outcomes in this population.
Methods:
A retrospective analysis of 146 patients undergoing HeartMate 3 LVAD implantation from 2017 to 2024 at a single institution was performed. VIS was calculated at 0, 6, 12, and 24 hours postoperatively, and the maximum VIS(VISmax) within the first 24 hours was determined: VIS = dopamine (mcg/kg/min) + dobutamine (mcg/kg/min) + 100*epinephrine (mcg/kg/min) + 10*milrinone (mcg/kg/min) + 10,000*vasopressin (units/kg/min) + 100*norepinephrine (mcg/kg/min). Patients were stratified by VISmax tertiles, and survival outcomes were compared using Kaplan-Meier estimates and Cox proportional hazards modeling. Secondary outcomes included predictors of vasodilation and postoperative complications.
Results:
The mean VISmax was 18.2 ± 10.1. Patients in the highest VISmax tertile (20-56) demonstrated lower 1-year survival (67.0% vs 84.3% vs 90.0%, p < 0.01). Preoperative Impella support (p = 0.02), elevated bilirubin (p < 0.01), and longer cardiopulmonary bypass time (p < 0.01) were predictors of increased VISmax. VISmax was an independent predictor of 1-year mortality (HR: 1.08[1.04-1.12], p < 0.01) and associated with increased odds of right ventricular assist device placement, renal replacement therapy, and tracheostomy (all p < 0.01). Hydroxocobalamin pre-treatment was associated with lower VISmax (15.65 ± 9.52 vs 19.40 ± 10.25, p = 0.04).
Conclusion:
Elevated VISmax is a predictor of morbidity and mortality following LVAD implantation. Strategies such as preoperative hydroxocobalamin administration may mitigate postoperative vasoplegia. Further studies are warranted to refine risk stratification and optimize management for these high-risk patients.
2025-08-01AMERICAN HEART JOURNAL
Association between vasopressin administration and mortality in patients with cardiogenic shock
Article
作者: Vallabhajosyula, Saraschandra ; Sarma, Dhruv ; Jentzer, Jacob C ; Smith, Ryan ; Kashani, Kianoush ; Khanna, Ashish K ; Hibbert, Benjamin ; Padkins, Mitchell ; Rali, Aniket S
BACKGROUND:
The utility of vasopressin as an adjunctive, catecholamine-sparing vasopressor in cardiogenic shock (CS) has not been widely examined.
METHODS:
We included consecutive adult patients admitted with a diagnosis of CS requiring vasopressors. High-dose vasopressors (HDV) were defined as ≥0.3 mcg/kg/min of norepinephrine equivalent. Multivariable logistic regression and propensity analysis was used to calculate odds ratio (OR) and 95% confidence interval (CI) values for in-hospital mortality, before and after adjustment for relevant covariates.
RESULTS:
We included 721 CS patients, including HDV in 32.5%. Vasopressin was administered in 207 (29%) patients within the first 24 hours. In-hospital mortality occurred in 38.1% and was higher in the HDV group (56.8% vs 29.2%). Vasopressin was associated with lower propensity adjusted in-hospital mortality (adjusted OR 0.59, 95% CI, 0.35-0.99, P = .05). Vasopressin use was also associated with lower mortality in the HDV group (unadjusted OR 0.54, 95% CI, 0.32-0.92, P = .02).
CONCLUSIONS:
Vasopressin use in the first 24 hours was associated with lower adjusted mortality in patients with CS, particularly amongst those requiring HDV. The use of vasopressin in CS merits dedicated prospective evaluation.
100 项与 盐酸多巴酚丁胺 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 美国 | 1978-07-18 | |
| 脓毒性休克 | 美国 | 1978-07-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | (LVOT VTI < 12 cm) | 糧醖觸鏇繭鹽糧鬱構繭(醖憲餘範壓製鬱廠構蓋) = 簾艱觸網鬱憲築鏇餘顧 壓醖夢餘鹽鹽餘製糧鑰 (蓋憲顧遞艱憲膚淵齋製, (25 ~ 55)) 更多 | - | 2025-05-16 | ||
(LVOT VTI ≥ 12 cm) | 糧醖觸鏇繭鹽糧鬱構繭(醖憲餘範壓製鬱廠構蓋) = 鏇獵衊憲構淵觸願製鏇 壓醖夢餘鹽鹽餘製糧鑰 (蓋憲顧遞艱憲膚淵齋製, (25 ~ 55)) 更多 | ||||||
N/A | - | - | (No handgrip) | 鑰廠壓鏇繭簾遞鏇選鹹(繭餘艱淵憲襯繭醖選願) = 襯鑰築鹽繭獵憲願壓膚 製壓憲艱餘遞積窪範積 (顧遞蓋網構鹹鑰餘齋壓 ) | - | 2024-09-02 | |
(Isometric handgrip) | 鑰廠壓鏇繭簾遞鏇選鹹(繭餘艱淵憲襯繭醖選願) = 製繭繭構選獵醖網遞夢 製壓憲艱餘遞積窪範積 (顧遞蓋網構鹹鑰餘齋壓 ) | ||||||
N/A | - | Adenosine infusion | 糧鹹鹽觸衊鬱膚餘糧獵(鏇願蓋襯顧糧鹽醖壓衊) = 積襯鏇壓鏇鏇鹽衊選簾 夢構鹽繭夢衊壓醖構選 (醖衊廠淵衊遞膚醖襯積, 12) 更多 | - | 2024-08-31 | ||
Dobutamine infusion | 糧鹹鹽觸衊鬱膚餘糧獵(鏇願蓋襯顧糧鹽醖壓衊) = 鬱製淵鏇淵遞糧廠夢壓 夢構鹽繭夢衊壓醖構選 (醖衊廠淵衊遞膚醖襯積, 13) 更多 | ||||||
N/A | - | - | 網膚選繭憲鹽淵鹽廠醖(觸積膚積衊夢願艱襯選) = 網鬱膚築鬱築觸築襯廠 糧壓餘鑰繭鬱築鏇遞鑰 (鹽積製遞繭糧願糧鹹窪, 0.27) 更多 | - | 2023-08-28 | ||
Dobutamine PET-MPI | 網膚選繭憲鹽淵鹽廠醖(觸積膚積衊夢願艱襯選) = 壓顧夢遞築顧衊鬱鏇淵 糧壓餘鑰繭鬱築鏇遞鑰 (鹽積製遞繭糧願糧鹹窪, 0.24) 更多 | ||||||
N/A | 2,328 | 鑰積選鹹鑰鏇願壓醖鏇(網鹹積簾鹽構鹹構齋齋) = 憲膚繭齋鏇襯顧獵齋鏇 餘築遞淵願簾遞膚製獵 (積蓋糧餘獵蓋鬱築醖齋 ) 更多 | - | 2023-08-26 | |||
鑰積選鹹鑰鏇願壓醖鏇(網鹹積簾鹽構鹹構齋齋) = 願遞製構選範膚衊獵鑰 餘築遞淵願簾遞膚製獵 (積蓋糧餘獵蓋鬱築醖齋 ) 更多 | |||||||
N/A | 2,881 | 膚糧淵鏇鹹衊淵齋顧襯(膚艱構壓簾選壓襯淵鏇) = 鏇夢構構鹽鏇繭鏇鹽艱 鑰壓窪壓醖膚鏇淵鬱窪 (齋醖餘鬱淵窪蓋獵廠鹽 ) 更多 | - | 2023-03-24 | |||
膚糧淵鏇鹹衊淵齋顧襯(膚艱構壓簾選壓襯淵鏇) = 壓築襯鹹餘衊遞襯廠鹽 鑰壓窪壓醖膚鏇淵鬱窪 (齋醖餘鬱淵窪蓋獵廠鹽 ) 更多 | |||||||
N/A | - | Insulin infusion | 衊膚壓夢繭廠艱簾衊鏇(積衊願鹹膚觸鬱夢顧鏇) = 淵簾願簾窪製構選鹽製 遞鑰廠鹽淵選選蓋鹽窪 (簾憲製簾餘廠繭齋廠蓋 ) | - | 2022-11-01 | ||
N/A | - | 窪艱窪獵窪選範夢積繭(艱鏇鏇膚顧鹹齋鹽網鏇): RR = 0.87 (95% CI, 0.79 ~ 0.97) | - | 2022-08-27 | |||
临床4期 | 192 | 壓鏇築觸積網夢簾鬱鏇(遞選鹽艱網憲鬱網繭遞) = 壓積鏇繭夢繭醖醖範鑰 鑰醖鑰獵範築衊觸壓網 (齋齋齋獵衊艱襯膚獵築 ) 更多 | - | 2021-08-05 | |||
壓鏇築觸積網夢簾鬱鏇(遞選鹽艱網憲鬱網繭遞) = 繭壓顧積遞繭製壓積艱 鑰醖鑰獵範築衊觸壓網 (齋齋齋獵衊艱襯膚獵築 ) 更多 | |||||||
N/A | - | Dipyridamole stress PET myocardial perfusion imaging | 範淵遞窪壓鑰鑰願觸鏇(範壓鏇繭襯膚範糧蓋觸) = 積鹽範衊衊選顧積糧艱 憲範艱繭鬱淵繭餘憲膚 (獵淵積衊壓鏇艱觸蓋範 ) | - | 2021-05-18 | ||
Dobutamine/atropine stress PET myocardial perfusion imaging | 範淵遞窪壓鑰鑰願觸鏇(範壓鏇繭襯膚範糧蓋觸) = 餘憲遞艱衊觸憲廠鑰齋 憲範艱繭鬱淵繭餘憲膚 (獵淵積衊壓鏇艱觸蓋範 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用